Colchicine Use in Crohn's Disease
Evidence Against Colchicine Use in Crohn's Disease
- Current clinical guidelines for the management of Crohn's disease do not include colchicine as a recommended treatment option for either induction or maintenance therapy, as stated by the European Crohn's and Colitis Organisation (ECCO) and other guideline societies 1
- The European Crohn's and Colitis Organisation (ECCO) guidelines specifically recommend corticosteroids, immunomodulators, and biologics as the mainstay treatments for Crohn's disease flares and maintenance, with no mention of colchicine 2, 1
- The Canadian Association of Gastroenterology guidelines for pediatric Crohn's disease focus on enteral nutrition, corticosteroids, immunomodulators, and biologics without including colchicine in their treatment algorithms 3
Established Treatment Options for Crohn's Disease
- First-line treatments for Crohn's disease flares include corticosteroids (budesonide 9 mg/day for disease limited to ileum/ascending colon or systemic corticosteroids for more extensive disease), as recommended by the American Gastroenterological Association 1
- Maintenance therapy after achieving remission should include biologics (TNF inhibitors) with or without immunomodulators, or thiopurines (azathioprine, mercaptopurine) or methotrexate, according to the American College of Gastroenterology 1
- Mesalazine (5-ASA) is not recommended for induction or maintenance of remission in Crohn's disease, as stated by the European Crohn's and Colitis Organisation (ECCO) 2, 1
Limited Evidence for Colchicine in Other Inflammatory Conditions
- In the North American Clinical Management Guidelines for Hidradenitis Suppurativa, weak evidence supports the use of colchicine only in combination with minocycline for refractory mild-to-moderate disease, but not as monotherapy, as recommended by the American Academy of Dermatology 4
- The EULAR recommendations for calcium pyrophosphate deposition note that colchicine at 0.5 mg up to 3-4 times daily may be used for acute attacks of crystal arthritis, but make no mention of inflammatory bowel disease, according to the European League Against Rheumatism (EULAR) 5